Literature DB >> 3459461

Regulation of macrophage tumor necrosis factor production by prostaglandin E2.

S L Kunkel, R C Wiggins, S W Chensue, J Larrick.   

Abstract

We have studied the role of prostaglandin E2 on the modulation of tumor necrosis factor by immunologically elicited and lipopolysaccharide treated murine macrophages. Indomethacin, a potent inhibitor of prostaglandin E2 production, caused a dose dependent augmentation of lipopolysaccharide induced tumor necrosis factor production (2-3 fold at 10(-7) molar). Tumor necrosis factor was released into the extracellular environment and no activity was found to be associated with membrane or cytosolic fractions. Prostaglandin E2 added to the lipopolysaccharide treated cultures suppressed tumor necrosis factor in a dose dependent manner. In these studies, 10(-7) molar PGE2 reduced tumor necrosis factor production to basal levels. These data suggest that PGE2 may be a potent autoregulatory factor that dramatically influences tumor necrosis factor production.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459461     DOI: 10.1016/0006-291x(86)91224-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  52 in total

1.  Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats.

Authors:  S Cuzzocrea; E Mazzon; C Bevilaqua; G Costantino; D Britti; G Mazzullo; A De Sarro; A P Caputi
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Inhibition by 16,16-dimethyl prostaglandin E2 of tumor necrosis factor-alpha and interleukin-1beta production and messenger RNA expression in human monocytes stimulated by Helicobacter pylori.

Authors:  O Takaishi; T Arakawa; Y Fujiwara; T Fukuda; K Otani; K Yamasaki; K Higuchi; T Kuroki
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

3.  Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production.

Authors:  T Shimozato; M Iwata; H Kawada; N Tamura
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

Review 4.  The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsis.

Authors:  D J Bihari; J Tinker
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

5.  Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.

Authors:  D Vial; L Arbibe; N Havet; C Dumarey; B Vargaftig; L Touqui
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 6.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

7.  Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes.

Authors:  A Waage; O Bakke
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

8.  Effect of selenium and grape seed extract on indomethacin-induced gastric ulcers in rats.

Authors:  Amr M Abbas; Hussein F Sakr
Journal:  J Physiol Biochem       Date:  2013-03-01       Impact factor: 4.158

9.  Low-dose lipopolysaccharide (LPS) pretreatment of mouse macrophages modulates LPS-dependent interleukin-6 production in vitro.

Authors:  N Hirohashi; D C Morrison
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway.

Authors:  Kirsty F MacKenzie; Kristopher Clark; Shaista Naqvi; Victoria A McGuire; Gesa Nöehren; Yosua Kristariyanto; Mirjam van den Bosch; Manikhandan Mudaliar; Pierre C McCarthy; Michael J Pattison; Patrick G A Pedrioli; Geoff J Barton; Rachel Toth; Alan Prescott; J Simon C Arthur
Journal:  J Immunol       Date:  2012-12-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.